Plerixafor may reduce infection incidence in patients with WHIM syndrome. The data for each patient are presented in separate columns. Each infection is represented as a dot and plotted by the month it occurred in relation to the start of plerixafor therapy. The time on plerixafor is bounded by the red box. Note that data for P2 were unavailable for the 12-month period marked by the black box. For P3, the hatched box represents a gap in plerixafor administration for the purpose of clinical care.